Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)
25.52
+0.00 (0.00%)
NASDAQ · Last Trade: Jan 23rd, 7:41 AM EST
Detailed Quote
Previous Close
25.52
Open
-
Bid
25.60
Ask
25.85
Day's Range
N/A - N/A
52 Week Range
2.540 - 26.22
Volume
19,663
Market Cap
1.91B
PE Ratio (TTM)
-50.04
EPS (TTM)
-0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
6,826,239
Chart
About Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer. The company is primarily engaged in the discovery and development of immuno-oncology products, aiming to harness the body’s immune system to fight against various types of tumors. Corvus leverages its expertise in biologic compounds to create targeted treatments that enhance immune response while minimizing side effects. Through its ongoing research and clinical trials, the company seeks to provide new options for patients with unmet medical needs in oncology. Read More
Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.
Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted investor optimism.
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.
